Researchers' global estimates indicate that by 2025, some 268 million children aged 5 to 17 years may be overweight, including 91 million obese, assuming no policy interventions have proven effective at changing current trends.
Oct 8, 2016
Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.
Oct 8, 2016
Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 ...
Oct 8, 2016
As the NHS lurches from crisis to crisis, the UK's approach to health needs radical rethinking to create a healthy and health-creating society. Just as the founding of the NHS in 1948 was a great national movement creating ...
Oct 8, 2016
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress ...
Oct 8, 2016
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at ...
Oct 8, 2016
Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO ...
Oct 8, 2016
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today ...
Oct 8, 2016
